Matinas BioPharma (MTNB) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Needham Starts NeoVolta (NEOV) at Buy
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- S&P 500 ends lower; chips tumble and Moderna rallies
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 13, 2019 6:30 AM EST Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020  NIH-funded Phase 2 EnACT trial of MAT2203 in cryptococcal meningitis initiated in October Management to host conference call today, Wednesday, November 13th, at 8:00 a.m. ET Â
BEDMINSTER, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:... More
